Real-world evaluation and comparative outcomes of bimekizumab versus adalimumab or secukinumab in moderate-to-severe hidradenitis suppurativa: A nationwide inverse probability of treatment-weighted cohort study on behalf of the HS-SIDeMaST task force

Supplementary Material 1: Statistical methods Supplementary Material 2: Multivariable Logistic Regression Analyses of Predictors of IHS4-55 and HiSCR achievement at Weeks 12-16. Supplementary Material 3: Data stratified according to bimekizumab dose regimen Supplementary Material 4: Data stratified according to bimekizumab bio-naïve status Supplementary Material 5 -Figure 1: A 67-year-old woman with long-standing hidradenitis suppurativa, refractory to adalimumab, was switched to bimekizumab. (A) (C) show the baseline clinical presentation prior to bimekizumab initiation, with numerous draining fistulous lesions and severe skin pain. (B) (D) demonstrate the marked clinical improvement achieved after 36 weeks of treatment, characterized by a substantial reduction in purulent discharge and an overall improvement in patient-reported quality of life scores. Figure 2: (A) Percentage of patients achieving IHS4-55, defined as a ≥55% reduction from baseline in the IHS4 (International Hidradenitis Suppurativa Severity Score System), and HiSCR (Hidradenitis Suppurativa Clinical Response)thresholds, including HiSCR-50, HiSCR-75, and HiSCR-90, defined as a ≥50%, ≥75%, or ≥90% reduction in inflammatory lesion count (abscesses + inflammatory nodules), respectively, with no increase in abscesses or draining fistulas compared with baseline, at time point 1 (T1= weeks 12–16). (B) Percentage of patients achieving the same IHS4-55 and HiSCR50/75/90 response thresholds at time point 2 (T2= weeks 24 ± 4). Supplementary Material 6: Comparison of baseline demographics and disease severity by treatment Group